Formulation, Optimization and In Vitro Studies of Flutamide-loaded Nanostructured Lipid Carrier Based Oral Drug Delivery for Enhanced Anticancer Activity

IF 2.7 4区医学 Q2 PHARMACOLOGY & PHARMACY

Journal of Pharmaceutical Innovation Pub Date : 2024-08-27 DOI:10.1007/s12247-024-09859-1

Vidya Sabale, Manasi Nikam, Prafulla Sabale

{"title":"Formulation, Optimization and In Vitro Studies of Flutamide-loaded Nanostructured Lipid Carrier Based Oral Drug Delivery for Enhanced Anticancer Activity","authors":"Vidya Sabale, Manasi Nikam, Prafulla Sabale","doi":"10.1007/s12247-024-09859-1","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p>The purpose of this study was to formulate and evaluate nanostructured lipid carriers (NLCs) of the poorly water soluble anticancer drug Flutamide.</p><h3>Methods</h3><p>Flutamide-loaded NLCs were formulated by the melt-emulsification ultrasonication method using solid lipid (Precirol ATO 5), liquid lipid (Linseed oil) and surfactants (Tween 80 and Koliphor RH 40). Box Behnken design using 3 factors and 3 levels were utilized to study key cause impact relationship between independent and dependent variables.</p><h3>Results</h3><p>The optimized Flutamide NLCs further evaluated for different parameters. Scanning electron microscopy (SEM) and transmission electron microscopy (TEM) studies showed spherical morphology and smooth texture of Flutamide NLCs. The optimized Flutamide-loaded NLCs showed high encapsulation efficiency of 97.7 ± 4.98%. The in vitro drug release of 88.15 ± 1.16% was shown by optimized Flutamide NLCs and followed Korsemeyer-peppas kinetics with Fickian diffusion as a drug release mechanism. The in vitro cell line studies on PC3 cells showed satisfactory results.</p><h3>Conclusion</h3><p>NLCs could have great potential to deliver Flutamide by oral route in the treatment and management of prostate cancer by oral route.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"19 5","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical Innovation","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12247-024-09859-1","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

The purpose of this study was to formulate and evaluate nanostructured lipid carriers (NLCs) of the poorly water soluble anticancer drug Flutamide.

Methods

Flutamide-loaded NLCs were formulated by the melt-emulsification ultrasonication method using solid lipid (Precirol ATO 5), liquid lipid (Linseed oil) and surfactants (Tween 80 and Koliphor RH 40). Box Behnken design using 3 factors and 3 levels were utilized to study key cause impact relationship between independent and dependent variables.

Results

The optimized Flutamide NLCs further evaluated for different parameters. Scanning electron microscopy (SEM) and transmission electron microscopy (TEM) studies showed spherical morphology and smooth texture of Flutamide NLCs. The optimized Flutamide-loaded NLCs showed high encapsulation efficiency of 97.7 ± 4.98%. The in vitro drug release of 88.15 ± 1.16% was shown by optimized Flutamide NLCs and followed Korsemeyer-peppas kinetics with Fickian diffusion as a drug release mechanism. The in vitro cell line studies on PC3 cells showed satisfactory results.

Conclusion

NLCs could have great potential to deliver Flutamide by oral route in the treatment and management of prostate cancer by oral route.

Abstract Image

查看原文本刊更多论文

基于纳米结构脂质载体的氟他胺口服给药的配方、优化和体外研究，以增强抗癌活性

方法使用固体脂质（Precirol ATO 5）、液体脂质（亚麻籽油）和表面活性剂（吐温 80 和 Koliphor RH 40），通过熔融-乳化超声法配制氟他胺纳米结构脂质载体（NLCs）。采用 3 个因素和 3 个水平的盒式贝肯设计来研究自变量和因变量之间的关键影响关系。扫描电子显微镜（SEM）和透射电子显微镜（TEM）研究显示，氟他胺 NLCs 呈球形，质地光滑。优化后的氟他胺 NLCs 封装效率高达 97.7 ± 4.98%。优化后的氟他胺 NLCs 的体外药物释放率为 88.15 ± 1.16%，药物释放机制遵循 Korsemeyer-peppas 动力学和 Fickian 扩散作用。PC3细胞的体外细胞系研究结果令人满意。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Pharmaceutical Innovation PHARMACOLOGY & PHARMACY-

CiteScore

3.70

自引率

3.80%

发文量

审稿时长

>12 weeks

期刊介绍： The Journal of Pharmaceutical Innovation (JPI), is an international, multidisciplinary peer-reviewed scientific journal dedicated to publishing high quality papers emphasizing innovative research and applied technologies within the pharmaceutical and biotechnology industries. JPI''s goal is to be the premier communication vehicle for the critical body of knowledge that is needed for scientific evolution and technical innovation, from R&D to market. Topics will fall under the following categories: Materials science, Product design, Process design, optimization, automation and control, Facilities; Information management, Regulatory policy and strategy, Supply chain developments , Education and professional development, Journal of Pharmaceutical Innovation publishes four issues a year.